[1]Patent:US2010/152257,2010,A1.Locationinpatent:Page/Pagecolumn25
[2]Patent:WO2011/159550,2011,A2.Locationinpatent:Page/Pagecolumn80
[1]Patent:WO2011/159550,2011,A2
[1]Patent:WO2011/159550,2011,A2
[1]Patent:WO2011/159550,2011,A2
[1]Patent:WO2011/159550,2011,A2
Title: Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts.
Journal: Journal of medicinal chemistry 20120913
Title: Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.
Journal: The Journal of pharmacology and experimental therapeutics 20110301
Title: Castelino FV, et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum. 2011 May;63(5):1405-15.
Title: Ruisanchez E, et al. Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. FASEB J. 2014 Feb;28(2):880-90.
Title: Swaney, J. S., et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. Journal of Pharmacology and Experimental Therapeutics (2011), 336(3), 693-700.